ANALYST RECOMMENDATIONS : BP, Cardinal Health, Moderna, Meggitt, Unilever...
Some heavyweights this morning in our selection, including Unilever and BP Plc. In the foodservices sector, Morgan Stanley is upgrading Compass, while Berenberg is negative on Synthomer. Despite reporting earnings and sales that topped estimates for the latest quarter, Douglas Emmett and Moderna are both downgraded by analysts.
- Becton Dickinson: J.P. Morgan cut the recommendation to neutral from overweight. PT up 9% to $265
- Berkshire Hills: RBC starts coverage at New Sector Perform, PT $29
- BP Plc: Morgan Stanley upgraded from Underweight to Overweight with a target of GBP 342.
- Cairn Energy: Berenberg upgrades from Hold to Buy, targeting GBp 235.
- Cardinal Health: Deutsche Bank downgrades to hold from buy. PT up 0.9% to $51
- Compass: Morgan Stanley upgrades its weighting to overweight.
- Douglas Emmett: SMBC Nikko cut the recommendation to neutral from outperform. PT up 3.6% to $34
- Meggitt: Bernstein upgraded from Outperform to Market Perform, targeting GBP 800.
- OceanFirst: Piper Sandler raised the recommendation to overweight from neutral. PT up 18% to $24
- PageGroup: Jefferies remains Buy with target price raised to GBP 680 from GBP 620.
- Parker-Hannifin: Deutsche Bank downgrades to hold from buy. PT up 8.9% to $327
- Moderna: Piper Sandler cut the recommendation to neutral from overweight. PT up 6.9% to $445
- Sthree: Jefferies remains Buy with a target price raised from GBP 540 to GBP 570.
- Synthomer: Berenberg upgrades its buy rating to hold with a target of 550 GBp.
- Unilever: Morgan Stanley upgrades from Underweight to Overweight with a target of GBP 4,200.
By 
